Neumora Therapeutics Reports Q2 2026 Results; CEO Transition Announced

What Happened

• Neumora Therapeutics (NMRA) filed a Current Report on Form 8‑K on August 14, 2026 announcing its financial results for the quarter ended June 30, 2026 and a leadership transition.
• Effective August 14, 2026 (the Transition Date), President Joshua Pinto, Ph.D. will succeed Paul L. Berns as Chief Executive Officer; Mr. Berns will become Executive Chairperson of the Board. The Board approved the Leadership Transition on August 12, 2026. The press release is furnished as Exhibit 99.1 to the 8‑K.

Key Details

• Filing date: August 14, 2026; quarter reported: Q2 ended June 30, 2026.
• Leadership change effective: August 14, 2026; Board approval date: August 12, 2026.
• Joshua Pinto will continue to serve as President and was appointed a Class III director effective on the Transition Date, with a term expiring at the 2029 Annual Meeting.
• The press release with the Q2 results and the announcement was included as Exhibit 99.1 to the Form 8‑K.

Why It Matters

• The company reported its quarterly results and simultaneously announced an internal CEO succession, indicating a planned leadership transition with continuity (President promoted to CEO and outgoing CEO remaining as Executive Chair).
• For investors, the two items to review are the Q2 financial details in the press release (Exhibit 99.1) for revenue, earnings, cash position and guidance, and any forthcoming disclosures about Dr. Pinto’s background, governance role, or compensation tied to the CEO appointment. The 8‑K establishes the effective date and board approval, but does not include the detailed financial figures in the filing text — consult the attached press release and subsequent filings for full financials and additional background.